4 registrations that name astaxanthin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT07063056
Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation
No phase
Medinutra LLC
About 64 people
Started Jul 18, 2025
In plain words A study of astaxanthin in people 21 to 59, run by Medinutra LLC. It plans to enroll about 64 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 59; healthy volunteers accepted. Conditions: Triglycerides.
Triglyceride reading of 140-250 mg/dL
Age 21-59
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin (Longvida™); Half Dose Curcumin (Longvida™); Astaxanthin; Placebo Control
Registered summary
Two dietary supplements are each being compared to a placebo for the ability to help maintain triglycerides in the normal range. The subjects will be adult men and women with moderately high TG values. Serum triglycerides will be measured before and after 6 weeks of taking 1 capsule per day of either Longvida Curcumin, astaxanthin, or a placebo. A few side blood analysis will also be done. These measures are relevant to low level inflammation.
Where, as registered
1 US site in 1 state.
RecruitingNCT06589128
Efficacy of Investigator Product for the Amelioration of Digital Eye Strain in Children
No phase
Universiti Sains Malaysia
About 70 people
Started Oct 1, 2024
In plain words A study of astaxanthin in people 10 to 11, run by Universiti Sains Malaysia. It plans to enroll about 70 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 10 to 11. Conditions: Digital Eye Strain (DES).
Children with DES (CVS-Q score 6-18)
The exclusion criteria are on the listing.
What it tests, as registered
Astaxanthin Oral Capsule; Placebo
Registered summary
Computer vision syndrome (CVS), also referred to as Digital eye strain (DES), is a group of eye and vision problems caused by prolonged use of electronic devices. The American Optometric Association (APA) defines DES as a group of eye and vision-related problems caused by prolonged computer, tablet, e-reader, and cell phone use. Currently, for more than 20 years, DES has been recognised as a public health issue, and the terms DES are also used to describe the condition, attributed to the wide range of digital devices associated with potential problems.
Where, as registered
No US site; Malaysia (2).
RecruitingNCT07507682
Can Astaxanthin Help Manage Asthma in POlluted Areas?
No phase
Middlesex University
About 25 people
Starts May 15, 2026 (estimated)
In plain words A study of astaxanthin in people 18 and older, run by Middlesex University. It plans to enroll about 25 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Asthma (Diagnosis); Airway Inflammation; Airway Hyperresponsiveness.
Adults 18+ y
Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:
A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024)
Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment
8 more inclusion criteria and the exclusion criteria are on the listing.
This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
Not yet recruitingNCT07684391
Effect of Oral Astaxanthin Formula on Pulmonary Rehabilitation in Patients With COPD
No phase
China-Japan Friendship Hospital
About 140 people
Starts Jul 1, 2026 (estimated)
In plain words A study of astaxanthin in people 18 to 80, run by China-Japan Friendship Hospital. It plans to enroll about 140 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: COPD.
Patients who met the GOLD diagnostic criteria for stage II-IV COPD
Patients who met the indications for pulmonary rehabilitation training: mMRC score
3 or self-reported decline in physical function.
The exclusion criteria are on the listing.
What it tests, as registered
Astaxanthin; Pulmonary rehabilitation training
Registered summary
The goal of this clinical trial is to investigate whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve exercise capacity in patients with COPD. The main questions it aims to answer are: • whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve 6MWD in patients with COPD. The drug administration group will receive: * Two capsules of astaxanthin formula supplement daily for 8 weeks. * Pulmonary rehabilitation training: a total of 8 weeks, 2-3 times a week. The full summary is on the listing.